Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Merkel Cell × domatinostat × Clear all

Phase

Status

Withdrawn 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1 Carcinoma, Merkel Cell 1

Interventions

Nivolumab 6 Ipilimumab 4 pembrolizumab 3 talimogene laherparepvec 2 budigalimab 2 avelumab 2 atezolizumab 2 Radiotherapy 2 Everolimus 2 venetoclax 1 vatalanib 1 tremelimumab 1 temsirolimus 1 sapanisertib 1 rovalpituzumab tesirine 1 poly ICLC 1 oblimersen 1 lorvotuzumab mertansine 1 lanreotide 1 glucopyranosyl lipid-A 1 fludarabine 1 durvalumab 1 domatinostat 1 cixutumumab 1 cemiplimab 1 aldesleukin 1 Vinorelbine 1 Surgical Procedures, Operative 1 Sirolimus 1 Salts 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04393753 2024-05-08

MERKLIN2

4SC AG

Phase 2 Completed

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡